ROIV (Roivant Sciences Ltd. Common Shares)
Insider Trading Activity
Every open-market purchase and sale reported by ROIV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | Mayukh Sukhatme | President & CIO | MIXED | — | — |
| 2026-07-29 | Eric Venker | President & Immunovant CEO | MIXED | — | — |
| 2026-07-21 | JAMES C MOMTAZEE | Director | A | — | — |
| 2026-07-21 | Ilan Oren | Director | A | — | — |
| 2026-07-21 | Epperly Melissa B, | Director | A | — | — |
| 2026-07-02 | Matthew Gline | CEO | F | — | — |
| 2026-07-02 | Frank Torti | President and Vant Chair | F | — | — |
| 2026-07-02 | Mayukh Sukhatme | President & CIO | F | — | — |
| 2026-07-02 | Meghan Fitzgerald | Director | MIXED | — | — |
| 2026-07-01 | Epperly Melissa B, | Director | MIXED | — | — |
| 2026-06-29 | Mayukh Sukhatme | President & CIO | MIXED | — | — |
| 2026-06-26 | Eric Venker | President & Immunovant CEO | MIXED | — | — |
| 2026-06-23 | Richard Pulik | CFO | F | — | — |
| 2026-06-23 | Jennifer Humes | Chief Accounting Officer | F | — | — |
| 2026-05-22 | Richard Pulik | CFO | F | — | — |
| 2026-05-22 | Eric Venker | President & Immunovant CEO | MIXED | — | — |
| 2026-04-22 | Jennifer Humes | Chief Accounting Officer | A | — | — |
| 2026-04-22 | Richard Pulik | CFO | A | — | — |
| 2026-04-22 | Eric Venker | President & Immunovant CEO | MIXED | — | — |
| 2026-04-21 | JAMES C MOMTAZEE | Director | MIXED | — | — |
| 2026-04-21 | Epperly Melissa B, | Director | A | — | — |
| 2026-04-21 | Ilan Oren | Director | MIXED | — | — |
| 2026-04-20 | Matthew Gline | CEO | Sell | — | — |
| 2026-04-10 | Jennifer Humes | Chief Accounting Officer | Sell | — | — |
| 2026-04-02 | Frank Torti | President and Vant Chair | F | — | — |
| 2026-04-01 | Mayukh Sukhatme | President & CIO | MIXED | — | — |
| 2026-04-01 | Matthew Gline | CEO | MIXED | — | — |
| 2026-03-30 | Meghan Fitzgerald | Director | MIXED | — | — |
| 2026-03-24 | Jennifer Humes | Chief Accounting Officer | F | — | — |
| 2026-03-24 | Richard Pulik | CFO | F | — | — |
| 2026-03-19 | Eric Venker | President & Immunovant CEO | MIXED | — | — |
| 2026-03-18 | Epperly Melissa B, | Director | Sell | — | — |
| 2026-02-24 | Eric Venker | President & Immunovant CEO | F | — | — |
| 2026-02-24 | Richard Pulik | CFO | F | — | — |
| 2026-02-23 | Frank Torti | President and Vant Chair | MIXED | — | — |
| 2026-02-18 | Eric Venker | President & Immunovant CEO | MIXED | — | — |
| 2026-02-13 | QVT Financial LP | — | Sell | — | — |
| 2026-02-13 | Daniel Allen Gold | Director | Sell | — | — |
| 2026-02-13 | KEITH S MANCHESTER | Director | Sell | — | — |
| 2026-02-11 | Mayukh Sukhatme | President & CIO | MIXED | — | — |
| 2026-01-22 | Epperly Melissa B, | Director | MIXED | — | — |
| 2026-01-22 | Ilan Oren | Director | MIXED | — | — |
| 2026-01-22 | JAMES C MOMTAZEE | Director | MIXED | — | — |
| 2026-01-14 | Eric Venker | President & Immunovant CEO | MIXED | — | — |
| 2025-12-31 | Mayukh Sukhatme | President & CIO | MIXED | — | — |
| 2025-12-29 | Eric Venker | President & Immunovant CEO | MIXED | — | — |
| 2025-12-29 | Richard Pulik | CFO | MIXED | — | — |
| 2025-12-29 | Frank Torti | President and Vant Chair | MIXED | — | — |
| 2025-12-23 | Richard Pulik | CFO | F | — | — |
| 2025-12-19 | Mayukh Sukhatme | President & CIO | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 73,031,667 | — |
| — | 10%+ Owner | 47,011,612 | — |
| — | Director | 24,469,007 | — |
| — | President & CIO | 20,288,437 | — |
| — | Director | 17,075,732 | — |
| — | CEO | 16,659,945 | — |
| — | — | 15,928,113 | — |
| — | President and Vant Chair | 13,536,202 | — |
| — | President & Immunovant CEO | 1,813,063 | — |
| — | CFO | 276,420 | — |
| — | Chief Accounting Officer | 162,306 | — |
| — | Director | 121,004 | — |
| — | Director | 109,810 | — |
| — | Chief Accounting Officer | 109,782 | — |
| — | Director | 42,963 | — |
| — | Director | 17,017 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ROIV quote page; the site-wide leaderboard is on the insider transactions hub.